Lamivudine + Tenofovir disoproxil fumarate Tablet

The lamivudine + tenofovir disoproxil fumarate tablet is a fixed-dose combination antiretroviral medicine used in the management of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) infection. This dual-therapy combination works by inhibiting viral replication, helping reduce viral load, and supporting long-term disease control under medical supervision.

The lamivudine + tenofovir disoproxil fumarate combination is commonly prescribed to simplify treatment regimens and improve patient adherence. By combining two proven antiviral agents into a single tablet, it supports consistent dosing and effective viral suppression when taken as directed by a healthcare professional.

This solution complies with accepted pharmaceutical standards to guarantee clinical appropriateness, consistency, and dependability. The Lamivudine (300 mg) + Tenofovir Disoproxil Fumarate (300 mg) tablet is a well-known and reliable pharmaceutical solution that provides antiviral assistance of pharmaceutical quality and is a crucial component of contemporary pharmacological approaches to managing viral infections over the long term.

Product Features

• Fixed-dose combination antiviral tablet
• Contains Lamivudine 300mg and Tenofovir DF 300 mg.
• Used in HIV and chronic hepatitis B management
• Once-daily oral tablet for simplified dosing
• Pharmaceutical-grade quality standards

How It Helps

• Helps suppress HIV and HBV viral replication
• Supports long-term management of viral infections
• Assists in maintaining immune system function
• Reduces the risk of disease progression
• Improves treatment adherence with combination therapy